Ovid Therapeutics Inc.
OVID
$1.56
-$0.01-0.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.78% | -28.34% | 50.72% | 49.50% | 33.02% |
| Total Depreciation and Amortization | -29.85% | -0.18% | 10.55% | 7.92% | -31.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.13% | 108.99% | -2,109.97% | -932.02% | -610.02% |
| Change in Net Operating Assets | -216.85% | -183.92% | -68.67% | -106.29% | 426.59% |
| Cash from Operations | 34.44% | 24.26% | 1.60% | -22.23% | -34.41% |
| Capital Expenditure | 64.52% | 75.00% | -15.56% | -77.50% | 57.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 387.24% | 295.80% | 414.54% | 2,251.32% | -136.15% |
| Cash from Investing | 385.92% | 295.00% | 413.01% | 2,215.23% | -136.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.73% | -93.94% | -41.52% | 16.26% | 30.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.91% | -99.83% | -98.67% | -97.96% | 6,587.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -133.33% | -100.00% | -100.00% |
| Net Change in Cash | 113.19% | 96.95% | 70.15% | 95.85% | -5,067.88% |